Yael Renert-Yuval1, Emma Guttman-Yassky2. 1. Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York. 2. Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Emma.Guttman@mountsinai.org.
Abstract
OBJECTIVE: Atopic dermatitis (AD) is an increasingly common inflammatory skin disease undergoing significant revolution in recent years. New data on disease pathogenesis advanced the developments of novel therapeutics, mainly for patients with moderate to severe conditions, for whom treatment options have been largely insufficient for many years. DATA SOURCES: Review of recent studies investigating systemic treatments for AD. STUDY SELECTIONS: Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized. RESULTS: Multiple clinical trials of both nonspecific as well as specific agents revealed favorable outcomes in AD, including JAK inhibitors, a dual JAK/SYK inhibitor, a histamine H4R antagonist, antagonists of the TSLP/OX40L axis, an IL-22 inhibitor, and IL-33 and IL-17C antagonists. Importantly, negative trials were published as well (eg, phosphodiesterase 4 inhibitor, apremilast). CONCLUSION: In this rapidly evolving field of AD treatments, a completely new treatment paradigm will be available in the near future.
OBJECTIVE:Atopic dermatitis (AD) is an increasingly common inflammatory skin disease undergoing significant revolution in recent years. New data on disease pathogenesis advanced the developments of novel therapeutics, mainly for patients with moderate to severe conditions, for whom treatment options have been largely insufficient for many years. DATA SOURCES: Review of recent studies investigating systemic treatments for AD. STUDY SELECTIONS: Relevant literature concerning novel therapeutics for AD beyond targeted monoclonal antibodies antagonizing selectively interleukin (IL)-4 or IL-13 was obtained from a PubMed and clinicaltrials.gov search and summarized. RESULTS: Multiple clinical trials of both nonspecific as well as specific agents revealed favorable outcomes in AD, including JAK inhibitors, a dual JAK/SYK inhibitor, a histamine H4R antagonist, antagonists of the TSLP/OX40L axis, an IL-22 inhibitor, and IL-33 and IL-17C antagonists. Importantly, negative trials were published as well (eg, phosphodiesterase 4 inhibitor, apremilast). CONCLUSION: In this rapidly evolving field of AD treatments, a completely new treatment paradigm will be available in the near future.
Authors: Maria Maddalena Sirufo; Francesca De Pietro; Enrica Maria Bassino; Lia Ginaldi; Massimo De Martinis Journal: Int J Mol Sci Date: 2020-07-03 Impact factor: 5.923
Authors: Xin Yu; Meifang Wang; Linfeng Li; Lin Zhang; Matthew Tak Vai Chan; William Ka Kei Wu Journal: J Cell Mol Med Date: 2020-04-30 Impact factor: 5.310
Authors: Chul Hwan Bang; Ji Young Song; Yu Mee Song; Ji Hyun Lee; Young Min Park; Jun Young Lee Journal: J Clin Med Date: 2021-05-04 Impact factor: 4.241